• Finding My Purpose in Life Despite Duchenne Muscular Dystrophy
  • PPMD Wins Bipartisan Legislative Backing of Its Muscular Dystrophy Goals
  • True Accessibility for All: No Roadblocks, Please
  • Pamrevlumab, Potential Treatment for Fibrosis in DMD Patients, Named Orphan Drug by FDA
  • Learning to Be Social with Duchenne
  • Audentes Therapeutics Expanding Treatment Candidates for Duchenne MD and Myotonic Dystrophy Type 1
  • Single Dose of CRISPR Gene Therapy May Succeed as Long-term Treatment for DMD, Mouse Study Shows
  • I Push My Limitations by Setting Goals
  • Raising Both Dystrophin and Utrophin Levels May Rescue Muscles in DMD, Mouse Study Suggests
  • Focus on What You Can Do Rather Than What You Can’t
  • RNA-targeting Compound Shows Ability to Limit Muscle Damage in Early Myotonic Dystrophy Type 1 Study
  • Casimersen Shows Promising Phase 3 Results for DMD, May Open Door for FDA New Drug Application